Dostarlimab

Dostarlimab
Generic Name/API:Dostarlimab
Packaging:1box contains 1 vial of dostarlimab solution
Storage:Store at 2°C to 8°C
Dosage:For dosage information, please visit the General Information section.
Strength:500mg/10ml (50mg/ml)
Indication:Jemperli is an immunotherapy drug used to treat certain types of cancer, particularly endometrial cancer that is mismatch repair-deficient (dMMR). It belongs to a class of medications called PD-1 (programmed death-1) inhibitors. Jemperli is given as an intravenous (IV) infusion and is typically used when the cancer has progressed or does not respond to other treatments.

Jemperli (Dostarlimab)is primarily indicated for the treatment of adults with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) solid tumors, particularly in cases where the disease has progressed and no satisfactory alternative treatment options are available. It is approved for use in certain patients with dMMR recurrent or advanced endometrial cancer that has progressed on or after prior platinum-containing chemotherapy. Jemperli may also be used in other dMMR solid tumors, including colorectal and other cancers, under specific conditions. Its use is guided by biomarker testing to confirm the presence of dMMR or MSI-H status, which helps predict the likelihood of response to the therapy.

Strength:

500mg/10ml (50mg/ml) of dostarlimab solution is available in a single dose vial 

Dosage: 

The recommended dosage for adult patients taking Jemperli as approved by FDA are:

  • Dose 1 through Dose 4: 500 mg every 3 weeks
  • Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1,000 mg every 6 weeks 

Side Effects :

  • Nerve problems in arms, hands, legs, and feet
  • Tiredness
  • Nausea
  • Hair loss
  • Joint pain
  • Rash
  • Constipation
  • Diarrhea
  • Stomach-area (abdomen) pain
  • Shortness of breath
  • Decreased appetite
  • Urinary tract infections
  • Vomiting

The most common side effects of Jemperli when given alone include:

  • Tiredness and weakness
  • Low red blood cell count (anemia)
  • Diarrhea
  • Nausea
  • Constipation
  • Vomiting

Storage:

  • Store vials of Jemperli at 2°C to 8°C
  • Do not freeze the vial
  • Do not shake the vial
  • Severe or fatal immune mediated adverse reactions may occur therefore, close monitoring of patients is required.
  • Infusion related infections may occur.
  • Transplant related complications are reported.

Process to Import Medicine

FAQ

Jemperli is a prescription medication used as an immunotherapy to treat certain types of cancer. It is a PD-1 inhibitor that helps the immune system detect and attack cancer cells.

Jemperli is primarily used to treat:

  • Mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer that has progressed after prior treatment.
  • dMMR solid tumors (including colorectal and others) when other treatment options are not available.

It is given as an intravenous (IV) infusion, once every 3–6 weeks depending on the treatment schedule.

While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certification and possesses a valid operating license. These credentials confirm the supplier’s adherence to international standards for the proper distribution of medicinal products.

The Price of Jemperli (Dostarlimab) Injection in India Varies Since It Must Be Imported. Factors Such as Supplier Availability, Import Duties, and Currency Fluctuations Affect the Final Price. For the Latest Cost Details, Contact 24/7QUALITYMEDS at +91 9967979080.

To Buy Jemperli (Dostarlimab) Injection Online in India at a Genuine Price, Contact 24/7QUALITYMEDS. We Assist with Prescription Verification, Legal Import, Reliable Sourcing, and Safe Delivery to Help You Place Your Order Confidently.

Related products